Unlock instant, AI-driven research and patent intelligence for your innovation.

Applications of DCG (derivative of clostridium ghonii)

Through the combined use of the domesticated Clostridium gordonii MW-DCG-HNCv-18 strain and docetaxel, the problem of poor efficacy of traditional therapy in tumor hypoxic areas has been solved, and efficient targeting of non-small cell lung cancer has been achieved. Dissolves, significantly improving the therapeutic effect.

Active Publication Date: 2015-04-01
SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Third, most chemotherapeutic drugs are only effective on rapidly dividing tumor cells, but have poor efficacy on hypoxic tumor cells that have stopped dividing, stromal cells, and tumor tissue structures (fibronectin and collagen)
Moreover, traditional chemoradiotherapy often lacks specific attack on tumor cells
[0003] The anaerobic microenvironment of the tumor limits the curative effect of traditional radiotherapy, chemotherapy and virus therapy, but it provides a good opportunity for anaerobic bacteria to grow and exert oncolytic properties in the hypoxic zone of the tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] research method:

[0032] ① Establishment of non-small cell lung cancer model

[0033] Non-small cell lung cancer A549 cells were slowly injected into the subcutaneous part of the right back of female Balb / c-nu / nu nude mice (5 weeks old, 20g) by subcutaneous injection, until the tumor volume grew to 300mm 3 In vivo anti-tumor experiments were carried out.

[0034] ② Animal grouping and handling

[0035] Control group: n=15 (n represents the number of animals in each group), tail vein injection PBS damping fluid 0.2ml;

[0036] MW-DCG-HNCv-18 spore group: n=15, the first day the tail vein injection of spores, the dose is 3 × 10 8 pcs / (kg. body weight).

[0037] MW-DCG-LCv-26 spore group: n=15, the first day tail vein injection of spores, the dose is 3 × 10 8 pcs / (kg. body weight).

[0038] MW-DCG-CCv-17 spore group: n=15, the 1st day tail vein injection of spores, the dose was 3×10 8 pcs / (kg. body weight).

[0039] C.novyi–NT spore group: n=15 rats, spores were i...

Embodiment 2

[0054] research method:

[0055] ① Establishment of non-small cell lung cancer model

[0056] Non-small cell lung cancer A549 cells were slowly injected into the subcutaneous part of the right back of female Balb / c-nu / nu nude mice (5 weeks old, 20g) by subcutaneous injection, until the tumor volume grew to 300mm 3 , in vivo experiments were performed.

[0057] ② Animal grouping and handling

[0058] Control group: n=15, tail vein injection of PBS buffer 0.2ml;

[0059] Docetaxel group: n=15 rats, the tail vein injection of docetaxel on the 4th day and the 11th day, the dose is 20 mg / (kg.body weight), and the dose of docetaxel is the optimal dose.

[0060] MW-DCG-HNCv-18 spore group: n=15 rats were injected with MW-DCG-HNCv-18 spores by tail vein, 3×10 8 pcs / (kg. body weight).

[0061] MW-DCG-HNCv-18 spores combined with Cetuximab (cetuximab) group: n=15, the first day tail vein injection of MW-DCG-HNCv-18 spores, the dose was 3 × 10 8 each / (kg.body weight); Cetuximab (ce...

Embodiment 3

[0077] research method:

[0078] ① Establishment of non-small cell lung cancer model

[0079] Non-small cell lung cancer A549 cells were slowly injected into the subcutaneous part of the right back of female Balb / c-nu / nu nude mice (5 weeks old, 20g) by subcutaneous injection, until the tumor volume grew to 300mm 3 , in vivo experiments were performed.

[0080] ② Animal grouping and handling

[0081] Control group: n=15, tail vein injection of PBS buffer 0.2ml;

[0082] MW-DCG-HNCv-18 spores combined with docetaxel-1 group: n=15 rats were injected with MW-DCG-HNCv-18 spores via the tail vein on the first day at a dose of 0.5×10 8 Individual / (kg.body weight); On the 4th and 11th day, docetaxel was injected into the tail vein, the dose was 20mg / (kg.body weight).

[0083] MW-DCG-HNCv-18 spores combined with docetaxel-2 group: n=15 rats, the tail vein injection of MW-DCG-HNCv-18 spores on the first day, the dose was 1.0×10 8 Individual / (kg.body weight); On the 4th and 11th day...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to applications of a DCG (derivative of clostridium ghonii), particularly to an application of a DCG MW-DCG-HNCv-18 to preparation of medicines for treating the NSCLC (non-small cell lung carcinoma), and discloses a medicine which takes both the DCG MW-DCG-HNCv-18 and docetaxelas medicinal components. The fact that the DCG MW-DCG-HNCv-18 has the specific inhibition effect on the NSCLC is discovered for the first time, the inhibition effect on the NSCLC is significantly superior to those of other known similar strains at present, the inhibition effect on the NSCLC is more outstanding when combined with a docetaxel injection according to screening results, and a new way is provided for treatment of the NSCLC.

Description

technical field [0001] The present invention relates to the application of a domesticated strain of Clostridium ghonii (Derivatives of Clostridium ghonii, DCG), in particular to the application of the domesticated strain of Clostridium ghonii in the preparation of drugs for the treatment of non-small cell lung cancer (Non-small cell lung cancer, NSCLC). The application belongs to the technical field of biomedicine. Background technique [0002] The current understanding of the pathophysiology of solid tumors has increasingly turned to the unique microenvironment in which they grow. The central region of solid tumors is characterized by elevated interstitial pressure, decreased cellular pH, low oxygen content, and tumor cell heterogeneity. The tumor microenvironment is also an important reason for tumor metastasis, invasion, and insensitivity to traditional chemotherapy and radiotherapy. First of all, in the hypoxic or necrotic area contained in solid tumors, because the hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/742A61P35/00A61K31/337
CPCA61K31/337A61K35/742A61K2300/00A61P35/00Y02A50/30A61K9/19
Owner SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com